title: [Examination of s-1 therapy for adjuvant chemotherapy in patients with advanced gastric cancer].
abstract: OBJECTIVE
  In our department, S-1 has been administered for 1 year as postoperative adjuvant chemotherapy for advanced gastric cancer since 2000. It was started by a standard dosage of 4-week administration with 2 weeks rest since 2000(A group). However, since 2002, it was changed with the expectation of the reduction of side effects by 2-week administration with a one-week rest(B group). Treatment continuity, adverse events and efficacy in both A and B groups were examined.
  
  
  METHODS
  The subjects were 96 patients with fStage II, III A and III B who were treated with S-1 after curative operation between 2000 and 2006.
  
  
  RESULTS
  The percentage of patients who complied with the dosing instructions completely during a 1-year period was 70.2% in the A group and 77.6% in the B group. The incidence of Grade 3 and 4 toxicity was 1 nausea, 2 appetite loss, 1 neutropenia, 1 liver dysfunction in the A group and 1 nausea, 3 neutropenia in the B group, against, 76.6% in the A group and 44.9% in the B group, respectively, in the case of discontinuation, Thus, the trend in significantly high incidence in the A group was recognized. The 3-year survival rates in cases with a case of over 3 years were 88.5% in the A group and 87.5% in the B group, i. e., no difference.
  
  
  CONCLUSIONS
  Though the difference was not recognized in continuation rate, efficacy and adverse events in both A and B groups, there were significantly few withdrawal cases in the B group, and it seemed to be an effective medication method.
authors: Dept. of Surgery, Niigata Cancer Center Hospital, Japan.
authors: Koshi
authors: K
authors: Matsui
authors: Atsushi
authors: A
authors: Nashimoto
authors: Hiroshi
authors: H
authors: Yabusaki
authors: Satoru
authors: S
authors: Nakagawa
authors: Tatsuya
authors: T
authors: Nomura
authors: Yasumasa
authors: Y
authors: Takii
authors: Yoshiaki
authors: Y
authors: Tsuchiya
authors: Otsuo
authors: O
authors: Tanaka
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid